Abdera Therapeutics

Targeted radiotherapeutics hold the potential to transform the treatment of cancer, but the ability to finely tune radioisotope delivery, while sparing healthy tissue, remains a major challenge. Abdera is leveraging its proprietary ROVEr™ platform to engineer and develop new precision radiotherapeutics with tunable PK properties to maximize therapeutic effect while mitigating systemic toxicities in order to treat a broad range of solid tumors.

Our company, technology and team are purpose-built to attack cancer.